Replies to post #131191 on Biotech Values

[DewDiligence]

I am betting/hoping Bydureon getting approved next Jan2012. It is obvious to me exenatide is the best current drug in its class except for the inept crew of Dan Bradbury.

A few years ago this board had a survey to pick the worst biotech CEO of all time. Bradbury received a couple of votes, IIRC.